Continuous cerebroventricular administration ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Permalink :
Title :
Continuous cerebroventricular administration of dopamine: a new treatment for severe dyskinesia in parkinson's disease?
Author(s) :
Laloux, Charlotte [Auteur]
Gouel, Flore [Auteur]
LACHAUD, cedrick [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U1171
Lille Neurosciences & Cognition (LilNCog) - U 1172
Timmerman, Kelly [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U1171
Lille Neurosciences & Cognition (LilNCog) - U 1172
Do Van, Bruce [Auteur]
Jonneaux, Aurelie [Auteur]
Petrault, Maud [Auteur]
Garcon, Guillaume [Auteur]
IMPact de l'Environnement Chimique sur la Santé humaine (IMPECS) - ULR 4483
171461|||Impact de l'environnement chimique sur la santé humaine - ULR 4483 [IMPECS]
Rouaix, Nathalie [Auteur]
moreau, caroline [Auteur]
Lille Neurosciences & Cognition (LilNCog) - U 1172
Troubles cognitifs dégénératifs et vasculaires - U1171
Bordet, Regis [Auteur]
Lille Neurosciences & Cognition (LilNCog) - U 1172
Troubles cognitifs dégénératifs et vasculaires - U1171
Duce, James A. [Auteur]
Devedjian, Jean-Christophe [Auteur]
DEVOS, DAVID [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U1171
Lille Neurosciences & Cognition (LilNCog) - U 1172
Gouel, Flore [Auteur]

LACHAUD, cedrick [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U1171
Lille Neurosciences & Cognition (LilNCog) - U 1172
Timmerman, Kelly [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U1171
Lille Neurosciences & Cognition (LilNCog) - U 1172
Do Van, Bruce [Auteur]
Jonneaux, Aurelie [Auteur]
Petrault, Maud [Auteur]
Garcon, Guillaume [Auteur]

IMPact de l'Environnement Chimique sur la Santé humaine (IMPECS) - ULR 4483
171461|||Impact de l'environnement chimique sur la santé humaine - ULR 4483 [IMPECS]
Rouaix, Nathalie [Auteur]
moreau, caroline [Auteur]

Lille Neurosciences & Cognition (LilNCog) - U 1172
Troubles cognitifs dégénératifs et vasculaires - U1171
Bordet, Regis [Auteur]

Lille Neurosciences & Cognition (LilNCog) - U 1172
Troubles cognitifs dégénératifs et vasculaires - U1171
Duce, James A. [Auteur]
Devedjian, Jean-Christophe [Auteur]
DEVOS, DAVID [Auteur]

Troubles cognitifs dégénératifs et vasculaires - U1171
Lille Neurosciences & Cognition (LilNCog) - U 1172
Journal title :
Neurobiology of disease
Abbreviated title :
Neurobiol. Dis.
Volume number :
103
Pages :
24-31
Publication date :
2017-07-01
ISSN :
0969-9961
English keyword(s) :
L-dopa related motor complications
Parkinson''s disease
Dopamine
Treatment-disease modifying effect
Parkinson''s disease
Dopamine
Treatment-disease modifying effect
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
In Parkinson's disease (PD) depletion of dopamine in the nigro-striatal pathway is a main pathological hallmark that requires continuous and focal restoration. Current predominant treatment with intermittent oral administration ...
Show more >In Parkinson's disease (PD) depletion of dopamine in the nigro-striatal pathway is a main pathological hallmark that requires continuous and focal restoration. Current predominant treatment with intermittent oral administration of its precursor, Levodopa (l-dopa), remains the gold standard but pharmacological drawbacks trigger motor fluctuations and dyskinesia. Continuous intracerebroventricular (i.c.v.) administration of dopamine previously failed as a therapy because of an inability to resolve the accelerated dopamine oxidation and tachyphylaxia. We aim to overcome prior challenges by demonstrating treatment feasibility and efficacy of continuous i.c.v. of dopamine close to the striatum. Dopamine prepared either anaerobically (A-dopamine) or aerobically (O-dopamine) in the presence or absence of a conservator (sodium metabisulfite, SMBS) was assessed upon acute MPTP and chronic 6-OHDA lesioning and compared to peripheral l-dopa treatment. A-dopamine restored motor function and induced a dose dependent increase of nigro-striatal tyrosine hydroxylase positive neurons in mice after 7days of MPTP insult that was not evident with either O-dopamine or l-dopa. In the 6-OHDA rat model, continuous circadian i.c.v. injection of A-dopamine over 30days also improved motor activity without occurrence of tachyphylaxia. This safety profile was highly favorable as A-dopamine did not induce dyskinesia or behavioral sensitization as observed with peripheral l-dopa treatment. Indicative of a new therapeutic strategy for patients suffering from l-dopa related complications with dyskinesia, continuous i.c.v. of A-dopamine has greater efficacy in mediating motor impairment over a large therapeutic index without inducing dyskinesia and tachyphylaxia.Show less >
Show more >In Parkinson's disease (PD) depletion of dopamine in the nigro-striatal pathway is a main pathological hallmark that requires continuous and focal restoration. Current predominant treatment with intermittent oral administration of its precursor, Levodopa (l-dopa), remains the gold standard but pharmacological drawbacks trigger motor fluctuations and dyskinesia. Continuous intracerebroventricular (i.c.v.) administration of dopamine previously failed as a therapy because of an inability to resolve the accelerated dopamine oxidation and tachyphylaxia. We aim to overcome prior challenges by demonstrating treatment feasibility and efficacy of continuous i.c.v. of dopamine close to the striatum. Dopamine prepared either anaerobically (A-dopamine) or aerobically (O-dopamine) in the presence or absence of a conservator (sodium metabisulfite, SMBS) was assessed upon acute MPTP and chronic 6-OHDA lesioning and compared to peripheral l-dopa treatment. A-dopamine restored motor function and induced a dose dependent increase of nigro-striatal tyrosine hydroxylase positive neurons in mice after 7days of MPTP insult that was not evident with either O-dopamine or l-dopa. In the 6-OHDA rat model, continuous circadian i.c.v. injection of A-dopamine over 30days also improved motor activity without occurrence of tachyphylaxia. This safety profile was highly favorable as A-dopamine did not induce dyskinesia or behavioral sensitization as observed with peripheral l-dopa treatment. Indicative of a new therapeutic strategy for patients suffering from l-dopa related complications with dyskinesia, continuous i.c.v. of A-dopamine has greater efficacy in mediating motor impairment over a large therapeutic index without inducing dyskinesia and tachyphylaxia.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
CHU Lille
CNRS
Inserm
Institut Pasteur de Lille
Université de Lille
CNRS
Inserm
Institut Pasteur de Lille
Université de Lille
Collections :
Research team(s) :
Troubles cognitifs dégénératifs et vasculaires
Submission date :
2019-11-27T14:28:23Z
2020-02-19T12:17:01Z
2022-10-19T13:51:51Z
2022-10-21T15:21:08Z
2020-02-19T12:17:01Z
2022-10-19T13:51:51Z
2022-10-21T15:21:08Z
Files
- document
- Open access
- Access the document